HER2 Type Male Breast Cancer Successfully Treated with Pertuzumab, Trastuzumab, and Eribulin Therapy: A Case Report

Masahiro Kitada*, Shunsuke Yasuda, Masahiro Abe, Nana Yoshida, Satoshi Okazaki, Kei Ishibashi

Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan

Email: *k11111@asahikawa-med.ac.jp, s-yasuda@asahikawa-med.ac.jp, abem@asahikawa-med.ac.jp, kyokui080026@gmail.com, syugoshin.19851221@gmail.com, kei_dod@hotmail.com

Abstract

Background: Male breast cancer is rare, accounting for approximately 0.5% - 1.0% of all breast cancer cases; hormone-dependent luminal type male breast cancer is the most common. The proportion of hormone receptor-negative and human epithelial growth factor Receptor type 2-positive breast cancer is extremely low among male breast cancer. A patient with advanced HER2 type breast cancer, a rare male breast cancer, was successfully treated with pertuzumab, trastuzumab, and eribulin therapy. Case Presentation: A 75-year-old man presented to our hospital with induration of the right anterior chest and lymphoedema of the right upper limb. Based on the results of core needle biopsy, he was diagnosed with HER2 type invasive ductal carcinoma associated with bone metastasis (stage IV). Chemotherapy with pertuzumab, trastuzumab, and eribulin was started. The drugs were remarkably effective, and his lymphoedema tended to improve. Conclusion: We reported a successful case of chemotherapy and targeted therapy for a rare male breast cancer of HER2 positive and hormone negative type.

Keywords

Male Breast Cancer, HER2 Type

1. Background

Male breast cancer (MBC) is rare, accounting for approximately 0.5% - 1.0% of all breast cancer cases; hormone-dependent luminal type MBC is the most common.
The proportion of hormone receptor-negative and Human Epithelial growth factor Receptor type 2 (HER2)-positive breast cancer is extremely low among MBCs and accounts for 0.6% - 1.2% of MBCs; in such cases, the prognosis is often poor [1] [2] [3] [4]. Herein, we report our experience with advanced hormone receptor-negative and HER2-positive breast cancer.

2. Case

The patient visited our department with a 3-month history of induration of the right anterior chest, right upper limb edema, numbness, and pain. His height was 158 cm and weight was 59 kg. Induration with redness and nodules was observed on the entire right anterior chest; we also observed edema from the right neck to upper limb and enlarged axillary lymph nodes. Blood test showed no abnormal findings except for increased tumor marker levels (carcinoembryonic antigen (CEA), 50.7 ng/mL and cancer antigen 15-3 (CA15-3), 295 U/mL). Computer tomography (CT) revealed nodules right under the papilla and surrounding edema, a number of enlarged lymph nodes from the axilla to the right neck, lymphedema in the upper limb, and pleural effusion in the right lung (Figure 1). Positron emission tomography (FDG-PET) revealed multiple accumulations in the entire right mammary gland (maximum standardized uptake value, 6.8), enlarged lymph nodes from the right cervical to axillary regions and in the left axillary regions, and multiple accumulations in the ribs and spine (Figure 2). Core needle biopsy revealed invasive ductal carcinoma: histological grade II; Ki-67 index, 50%; estrogen receptor (ER) (−); progesterone receptor (PgR) (−); HER2 (3+); intrinsic subtype, HER2 type; and T4N3M1 Stage IV. We considered administration of pertuzumab, trastuzumab, and docetaxel; however, considering pleural effusion and edema from the right anterior chest to the upper limb, we initiated combination therapy with pertuzumab, trastuzumab, and eribulin. After completing 1 cycle, his edema and upper limb pain decreased markedly. After completing 3 cycles, CT showed reduction in lymph node swelling; moreover, a marked decrease was observed in tumor marker levels (CEA, 5.8 ng/mL and CA15-3, 57.5 U/mL) (Figure 3). He maintained partial response with chemotherapy, and no adverse reactions were observed. The treatment is still ongoing.

Figure 1. CT image at first visit: right axilla, cervical lymphadenopathy, mediastinal lymphadenopathy, right upper limb edema.
Figure 2. Positron emission tomography (FDG-PET) revealed multiple accumulations in the entire right mammary gland (maximum standardized uptake value, 6.8), enlarged lymph nodes from the right cervical to axillary regions and in the left axillary regions, and multiple accumulations in the ribs and spine.

Figure 3. CT image after completing 3 cycles chemotherapy, CT showed reduction in lymph node swelling.

3. Discussion

MBC is rare, accounting for 0.5% - 1.0% of all breast cancer cases; hormone-dependent luminal type MBC is the most common. The proportion of intrinsic HER2 subtype (hormone receptor-negative and HER2-positive) cancers among MBCs is as low as 0.6% - 1.2%. Patients with advanced recurrent breast cancer often have a poor prognosis [1] [2] [3] [4]. Of the 3194 breast cancer patients at our hospital between 2000 and 2018, 14 (0.44%) had MBC. Twelve patients had hormone-dependent (ER- and/or PgR-positive) and HER2-negative cancers. Of these, 10 patients are still alive without recurrence after oral administration of tamoxifen for 5 years; 2 patients with stage IIIb and stage IV disease at the initial visit died after 1 year and 8 months and 5 years and 8 months, respectively. One patient with hormone receptor-negative and HER2-positive breast cancer died early from multiple lymph nodes and lung metastases. Taken together, we believe that HER2 type MBCs are detected in the advanced stage.

In general, a combination of anticancer and anti-HER2 therapy is the standard treatment for HER2-positive advanced recurrent breast cancer. Recently, the usefulness of pertuzumab, trastuzumab, and docetaxel has also been reported [5]. However, docetaxel administration in patients with edema or pleural effusion requires careful attention, and its use is often difficult. In the 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC
3), pertuzumab and trastuzumab were suggested to be good (easy to use) anti-
cancer drugs in response to the HER2 positive ABC-Unanswered Questions for
HER2 positivity: “Are there better chemo partners with less toxicity for pertuzumab
and trastuzumab first line?” [6]. A phase II clinical study on pertuzumab,
trastuzumab, and eribulin therapy has also been conducted. Thus, we decided to
use eribulin in the present patient [7]. A phase III study compared previous
taxane/anthracycline therapy with eribulin-containing therapy (selected by at-
tending physicians) in terms of survival benefit in patients with advanced recur-
rent breast cancer. Their results showed that response rate, progression-free sur-
vival, and median overall survival were significantly high whereas adverse reac-
tions (such as peripheral neuropathy) were significantly low in the eribulin group.
Furthermore, subgroup analysis showed favorable results in HER2-positive pa-
tients [8]. Considering the limited reports on HER2-positive MBC and lack of
data supporting differences in treatment between men and women, we consid-
ered it appropriate to refer to such clinical studies for treatment in our present
case.

Furthermore, genetic breast cancer accounts for 5% - 10% of breast cancer
cases, and the proportion of breast cancer susceptibility gene (BRCA) muta-
tion-positivity is reportedly higher in MBC than in female breast cancers [9]
[10]. BRCA mutation-positive patients generally show HER2 negativity. This is
because both HER2 loci are located close to the BRCA-1 gene; furthermore, a
report has suggested that 8% - 10% BRCA mutation-positive patients are HER2-
positive [11]. Unlike anticancer drugs, poly ADP-ribose polymerase (PARP) in-
hibitors [12], which are currently available for patients with BRCA mutation-
positive advanced cancers, are relatively easy to use even in poor general
conditions. BRCA mutation testing may be an option, considering the use of
PARP inhibitors, in patients who are not eligible for receiving many drug alter-
natives, as observed in this case.

4. Conclusion
We reported a successful case of chemotherapy and targeted therapy for a rare
male breast cancer of HER2 positive and hormone negative type.

Availability of Data and Materials
All data generated or analyzed during this study are included in this published
article.

Ethics Approval and Consent to Participate
All procedures used in this research were approved by the Ethics Committee of
Asahikawa Medical University.

Authors Contribution
MK has operated this case and analyzed all data. SY, MA, NY, SO, KI did the as-
Assistant of chemotherapy. All authors read and approved the final manuscript.

**Consent for Publication**

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief of this journal.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**References**

[1] Leone, J.P., Leone, J., Zwenger, A.O., Iturbe, J., Vallejo, C.T. and Leone, B.A. (2015) Prognostic significance of tumor subtypes in male breast cancer: a population-based study. *Breast Cancer Research and Treatment*, 152, 601-609. [https://doi.org/10.1007/s10549-015-3488-y](https://doi.org/10.1007/s10549-015-3488-y)

[2] Masci, G., Caruso, M., Caruso, F., Salvini, P., Carnaghi, C., Giordano, L., Misericochi, V., Losurdo, A., Zuradelli, M., Torrisi, R., Di Tommaso, L., Tinterri, C., Testori, A., Garcia-Etienne, C.A., Gatzemeier, W. and Santoro, A. (2015) Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. *Oncologist*, 20, 586-592. [https://doi.org/10.1634/theoncologist.2014-0243](https://doi.org/10.1634/theoncologist.2014-0243)

[3] Chavez-Macgregor, M., Clarke, C.A., Lichtensztajn, D., Hortobagyi, G.N. and Giordano, S.H. (2013) Male Breast Cancer According to Tumor Subtype and Race: A Population-Based Study. *Cancer*, 119, 1611-1617. [https://doi.org/10.1002/cncr.27905](https://doi.org/10.1002/cncr.27905)

[4] Abreu, M.H., Afonso, N., Abreu, P.H., Menezes, F., Lopes, P., Henrique, R., Pereira, D. and Lopes, C. (2016) Male Breast Cancer: Looking for Better Prognostic Subgroups. *The Breast*, 26, 18-24. [https://doi.org/10.1016/j.breast.2015.12.001](https://doi.org/10.1016/j.breast.2015.12.001)

[5] Baselga, J., Cortés, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., Roman, L., Pedrini, J.L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M.C., Ross, G. and Swain, S.M. (2012) CLEOPATRA Study Group. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. *The New England Journal of Medicine*, 366, 109-111. [https://doi.org/10.1056/NEJMoai1113216](https://doi.org/10.1056/NEJMoai1113216)

[6] Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharryya, G., et al. (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *The Breast*, 31, 244-259. [https://doi.org/10.1016/j.breast.2017.01.001](https://doi.org/10.1016/j.breast.2017.01.001)

[7] Narui, K., Yamashita, T., Kitada, M., Kawaguchi, H., Hattori, M., et al. (2017) Eribulin in Combination with Pertuzumab plus Trastuzumab for HER2-Positive Advanced or Recurrent Breast Cancer (JBCRG-M03). *Journal of Clinical Oncology*, 35, 1025-1025. [https://doi.org/10.1200/JCO.2017.35.15_suppl.1025](https://doi.org/10.1200/JCO.2017.35.15_suppl.1025)

[8] Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J.L., Vahdat, L.T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., Vladimirov, V., Cardoso, F., Koh, H., Bougnoux, P., Dutcus, C.E., Seegobin, S., Mir, D., Meneses, N., Wanders, J. and Twelves, C. (2011) EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) Investigators. Eribulin Monotherapy versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer (EMBRACE): A Phase 3 Open-Label Randomised Study. *Lancet*, 377, 914-923.
Abbreviations

HER2: Human Epithelial Growth factor Receptor type 2
MBC: Male Breast Cancer
CT: Computer Tomography
FDG-PET: Fluorodeoxyglucose-Positron Emission Tomography
CEA: Carcinoembryonic Antigen
CA15-3: Cancer Antigen 15-3

BRCA: breast cancer susceptibility gene
PARP: Poly ADP-Ribose Polymerase

[9] Kwiatkowska, E., Teresiak, M., Filas, V., Karczewska, A., Breborowicz, D. and Mackiewicz, A. (2003) BRCA2 Mutations and Androgen Receptor Expression as Independent Predictors of Outcome of Male Breast Cancer Patients. Clinical Cancer Research, 9, 4452-4459.

[10] Hesse-Biber, S. and An, C. (2017) Within-Gender Differences in Medical Decision Making among Male Carriers of the BRCA Genetic Mutation for Hereditary Breast Cancer. American Journal of Men's Health, 11, 1444-1459.

[11] Vaziri, S.A., Krumroy, L.M., Elson, P., Budd, G.T., Darlington, G., Myles, J., Tubbs, R.R. and Casey, G. (2001) Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis. Clinical Cancer Research, 7, 1937-1945.

[12] Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., Wardley, A., Mitchell, G., Earl, H., Wickens, M. and Carmichael, J. (2010) Oral Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Patients with BRCA1 or BRCA2 Mutations and Advanced Breast Cancer: A Proof-Of-Concept Trial. Lancet, 376, 235-244.